Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes.

By D. Steensma, R. Bejar, Siddhartha Jaiswal, R. C. Lindsley, M. Sekeres, R. Hasserjian, Benjamin L. Ebert. Blood, 2015

1,824 citations recorded by the source corpus.

Subfields: Cancer Research, Genetics, Hematology

View Paper: https://www.semanticscholar.org/paper/3d77c8cca58f91277e5c9b6f1d2d3a2a886aab7b

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cancer Research

1. Benjamin L. Ebert
2. Grant A. Challen
3. A. Young
4. Siddhartha Jaiswal
5. Brenda M. Birmann
6. T. Druley

In Genetics

1. Benjamin L. Ebert
2. Grant A. Challen
3. A. Young
4. Andreas Hochhaus
5. Siddhartha Jaiswal
6. Brenda M. Birmann
7. T. Druley
8. H. Kantarjian

In Hematology

1. J. Apperley
2. J. Baselga
3. Benjamin L. Ebert
4. Grant A. Challen
5. A. Young
6. Andreas Hochhaus
7. Siddhartha Jaiswal
8. Brenda M. Birmann

Citations in the corpus

• The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. (2016, positive): “Importantly, acquired clonal mutations identical to those seen inMDS can occur in the hematopoietic cells of apparently healthy older individuals without MDS, so-called “clonal hematopoiesis of indeterminate potential” (CHIP).(30,31,61) Although some patients with CHIP subsequently developMDS, the n”
• Clonal haematopoiesis harbouring AML-associated mutations is ubiquitous in healthy adults (2016, positive): “This facilitated the investigation of benign clonal haematopoiesis in younger individuals, previously thought to only rarely harbour haematopoietic clones 8–12 .”
• Clonal hematopoiesis in human aging and disease (2019, positive): “CHIP refers to the presence of a cancer-associated variant in the blood cells of a person without a frank malignancy or another recognized clonal entity, such as monoclonal B-lymphocytosis (MBL) or paroxysmal nocturnal hemoglobinuria (40).”
• The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms (2022, background): “Clonal haematopoiesis of indeterminate potential (CHIP) is defined in the classification as a term referring specifically to CH harbouring somatic mutations of myeloid malignancy-associated genes detected in the blood or bone marrow at a variant allele fraction (VAF) of ≥ 2% (≥4% for X-linked gene m”
• Therapy-related clonal hematopoiesis in patients with non-hematologic cancers is common and impacts clinical outcome (2017, background): “CH (also referred to as clonal hematopoiesis of indeterminate potential [CHIP] and age-related clonal hematopoiesis [ARCH]) is thought to be analogous to other precursor clonal states, such as monoclonal gammopathy of undetermined significance (MGUS) and monoclonal B cell lymphocytosis (MBL) (Ogawa,”
• Revisiting the hallmarks of cancer. (2017, neutral): “[213] Steensma DP, Bejar R, Jaiswal S, Lindsley RC, Sekeres MA, Hasserjian RP and Ebert BL.”